Bill s415-117 would narrow the FDA's definition of "active ingredient" to "active moiety" in certain drug approval situations, affecting the Pharmaceuticals & Biotech industry. Senator Bill Cassidy (R-LA) introduced this bill. Pharmaceuticals & Biotech contributed 6.4% of Cassidy's identifiable donor base ($1.38M), ranking 13th among donor industries within their party.

FOLLOW THE TRAIL
How we built this: a statistical pattern surfaced from public records — FEC campaign finance, Senate/House Lobbying Disclosure Act filings, and Congress.gov. The donor concentration and the legislative action are concurrent facts; this does not imply contributions caused the action, that the member acted improperly, or that the bill specifically benefits the named sector. Generated June 13, 2026 · internal signal score 61/100.